Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CS-002 · 1 trial · 2 indications
Greying Severity Score (GSS). Mild Greying score between 0-5, Moderate Greying score between 6-10 and Severe Greying score between 11-15
| Arm | Type | Description |
|---|---|---|
| CS-002 | EXPERIMENTAL | CS-002 Topical Treatment |
| Placebo | PLACEBO_COMPARATOR | Placebo Topical Treatment |
| Name | Type | Description |
|---|---|---|
| CS-002 | DRUG | CS-002 Topical Treatment |
| Placebo Topical Solution | DRUG | Placebo Topical Solution |
Inclusion Criteria: * Age 30 to 65 * Diagnosed with Grey Hair (Canities) * Willing and able to apply the treatment as directed, comply with study * Otherwise healthy * Able to give informed consent Exclusion Criteria: * A medical history that may interfere with study objectives * Women who are pr...
CS-002 is an investigational small molecule being developed for the treatment of canities, commonly known as grey hair. It is currently in Phase 1 clinical development and has not yet been approved by regulatory authorities.
CS-002 is an mTOR inhibitor, meaning it targets the mTOR pathway. The drug is being studied for its potential to treat canities, or grey hair, by modulating this cellular signaling pathway.
CS-002 is being developed by Applied Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol APLT. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
CS-002 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied in a randomized, double-blind, placebo-controlled trial.
CS-002 is being evaluated in a Phase 1 clinical trial registered as NCT07166354, titled 'Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities).' The trial is not yet recruiting and plans to enroll 100 participants aged 30 years and older.